OBJECTIVES: WAYFIND-R (NCT04529122), a global, prospective pan-cancer precision oncology registry of patients diagnosed with a malignant solid tumor profiled with next-generation sequencing (NGS), collects long-term, high-quality real-world data on those patients’ characteristics and outcomes, as well as socioeconomic factors. It aims to be a fit-for-purpose data source for researchers internationally.

METHODS: Patient data are standardized and collected longitudinally into a centralized database. These include comorbidities, tumor characteristics, biomarker, NGS and molecular tumor board decision-making, cancer treatment and outcomes. Here we describe patients' sociodemographic and socioeconomic characteristics.

RESULTS: As of 30 April 2023, 976 patients from 64 sites, mostly academic institutions/university hospitals across 24 countries (Europe: 527 patients; South America: 150; Middle East: 176; Asia: 112; Africa and North America: 11), had complete baseline and cancer diagnosis information. Median age was 64 years (range: 20–93) and 51% of patients were female. Race/ethnicity was available for 675 patients (White: 73%; Asian: 17%; Mixed or other [mostly Hispanic]: <10%; Black: <10%). Overall, 116 cancer types were included and 82% of patients had metastatic disease when enrolled. The most common cancer types were lung (n=289), colon (n=105), pancreas (n=90), breast (n=69) and ovary (n=34). Sixty-six per cent of all patients had their treatment reimbursed. Out-of-pocket payment varied across regions (Europe: <10%; South America: <10%; Middle East: 21%; Asia: 51%), as did educational level (tertiary education: 24%, 53%, 38% and 39%, respectively) and government insurance (84%, 19%, 55% and 79%, respectively).

CONCLUSIONS: The WAYFIND-R database provides insights into some social determinants of health that may influence patient care pathways, from which further epidemiological and health economic studies are encouraged.